Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
KALA

KALA - Kala Pharmaceuticals Inc Stock Price, Fair Value and News

$0.57-0.02 (-3.39%)
Market Closed

3/100

KALA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

3/100

KALA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.49

Target 3M

$0.55

Target 6M

$0.52

KALA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KALA Price Action

Last 7 days

-5%

Last 30 days

-1.7%

Last 90 days

-25%

Trailing 12 Months

-93.5%

KALA RSI Chart

KALA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KALA Valuation

Market Cap

4.7M

Price/Earnings (Trailing)

-0.13

Price/Sales (Trailing)

0.84

Price/Free Cashflow

-0.13

KALA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.49

Target 3M

$0.55

Target 6M

$0.52

KALA Fundamentals

KALA Revenue

Revenue (TTM)

5.6M

Rev. Growth (Yr)

-75.33%

Rev. Growth (Qtr)

-12.25%

KALA Earnings

Earnings (TTM)

-35.8M

Earnings Growth (Yr)

15.49%

Earnings Growth (Qtr)

32.19%

KALA Profitability

Return on Equity

413.63%

Return on Assets

-143.24%

Free Cashflow Yield

-778.82%

KALA Investor Care

Shares Dilution (1Y)

78.08%

Diluted EPS (TTM)

-5.35

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20257.5M7.0M5.6M0
20245.9M6.9M5.9M6.2M
2023005.5M5.2M
20229.3M8.4M5.7M3.9M
20218.6M10.8M11.6M11.2M
20205.8M4.5M5.3M6.4M
20190006.1M
20150000
Get all data in R, Python etc through our Historical Stock Data APIs

About Kala Pharmaceuticals Inc

KALA
KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
 CEO
 WEBSITEkalarx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES34

Kala Pharmaceuticals Inc Frequently Asked Questions

KALA is the stock ticker symbol of Kala Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Kala Pharmaceuticals Inc is 4.68 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check KALA's fair value in chart for subscribers.

The fair value guage provides a quick view whether KALA is over valued or under valued. Whether Kala Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Kala Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KALA.

As of Wed Jan 28 2026, KALA's PE ratio (Price to Earnings) is -0.13 and Price to Sales (PS) ratio is 0.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KALA PE ratio will change depending on the future growth rate expectations of investors.